HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance

HER2 receptor tyrosine kinase that is overexpressed in approximately 20% of all breast cancers (BCs) is a poor prognosis factor and a precious target for BC therapy. Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Nami, Babak, Wang, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447950/
https://www.ncbi.nlm.nih.gov/pubmed/28445439
http://dx.doi.org/10.3390/cancers9050040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447950/
https://www.ncbi.nlm.nih.gov/pubmed/28445439
http://dx.doi.org/10.3390/cancers9050040

Ejemplares similares